`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`
`Petitioner,
`
`v.
`
`BAUSCH HEALTH IRELAND LIMITED,
`
`Patent Owner.
`
`__________________
`
`Case IPR2022-00722
`U.S. Patent No. 7,041,786
`__________________
`
`PATENT OWNER’S MOTION TO SEAL AND
`ENTER DEFAULT PROTECTIVE ORDER
`
`
`
`
`
`
`
`
`
`
`Introduction
`Patent Owner Bausch Health Ireland Limited requests that the confidential
`
`Case IPR2022-00722
`U.S. Patent No. 7,041,786
`
`
`I.
`
`versions of the Patent Owner’s Response and Exhibits 2023, 2024, 2025, 2027, and
`
`2028 be sealed under 37 C.F.R. § 42.54. Good cause to seal these documents exists
`
`because a public version of the Patent Owner’s Response, Exhibits 2023, 2024 and
`
`2025 have also been filed, and the redacted information, along with the entirety of
`
`the information in Exhibits 2027 and 2028, is sensitive, non-public excerpts of
`
`Bausch’s New Drug Application (“NDA”). Petitioner does not oppose this motion
`
`to seal or the entry of the default protective order, provided that Petitioner may seek
`
`additional restrictions to the default order if Petitioner’s confidential information is
`
`proposed to be submitted later.
`
`II. Governing Rules and PTAB Guidance
`Under 35 U.S.C. § 316(a)(1), the default rule is that all papers filed in an inter
`
`partes review are open and available for access by the public, but a party may file a
`
`concurrent motion to seal and the information at issue is sealed pending the outcome
`
`of the motion.
`
`Similarly, 37 C.F.R. § 42.14 provides:
`
`The record of a proceeding, including documents and things,
`shall be made available to the public, except as otherwise
`ordered. A party intending a document or thing to be sealed
`shall file a motion to seal concurrent with the filing of the
`
`
`
`
`
`
`
`Case IPR2022-00722
`U.S. Patent No. 7,041,786
`
`document or thing to be sealed. The document or thing shall be
`provisionally sealed on receipt of the motion and remain so
`pending the outcome of the decision on the motion.
`
`It is, however, only “confidential information” that is protected from disclosure. 35
`
`U.S.C. § 316(a)(7) (“The Director shall prescribe regulations -- . . . providing for
`
`protective orders governing the exchange and submission of confidential
`
`information”). In that regard, the Office Trial Practice Guide, 77 Fed. Reg. 48756,
`
`48760 (Aug. 14, 2012) provides:
`
`The rules aim to strike a balance between the public’s interest
`in maintaining a complete and understandable file history and
`the parties’ interest in protecting truly sensitive information.
`* * *
`Confidential Information: The rules identify confidential
`information in a manner consistent with Federal Rule of Civil
`Procedure 26(c)(1)(G), which provides for protective orders for
`trade secret or other confidential research, development, or
`commercial information. § 42.54.
`
`Identification of Confidential Information
`The confidential information consists of non-public excerpts of Bausch’s
`
`III.
`
`NDA. This information is contained in the following documents:
`
`• Patent Owner’s Response in pages 58-65
`
`• Exhibit 2023 in pages 4-14
`
`2
`
`
`
`
`
`Case IPR2022-00722
`U.S. Patent No. 7,041,786
`
`• Exhibit 2024 in pages 101, 102, 105-112, and 114-118
`
`• Exhibit 2025 in pages 49-53 and 56-59
`
`• Exhibit 2027
`
`• Exhibit 2028
`
`IV. Good Cause Exists for Sealing the Confidential Information
`The Board’s rules identify confidential information in a manner consistent
`
`with Federal Rule of Civil Procedure 26(c)(1)(G), which provides for protective
`
`orders for trade secret or other confidential research, development, or commercial
`
`information. Office Patent Trial Practice Guide, 77 Fed. Reg. 48,756, 48,760 (Aug.
`
`14, 2012). Accordingly, the Board has recognized that New Drug Applications and
`
`Abbreviated New Drug Applications contain confidential commercial information
`
`that should be protected from public disclosure. See Sandoz, Inc. v. EKR
`
`Therapeutics, LLC, IPR2015-00005, paper 21. Here, the information that Patent
`
`Owner seeks to seal is information contained in Bausch’s NDA, which was filed
`
`confidentially with the Food and Drug Administration (“FDA”) in order to obtain
`
`FDA approval to market its innovative pharmaceutical product. Specifically, Patent
`
`Owner seeks to seal the entirety of Exhibits 2027 and 2028 because they are excerpts
`
`of the NDA, the entirety of which is confidential, and redaction would not be
`
`practical. In addition, Patent Owner seeks to seal the portions of the Patent Owner’s
`
`Response, pages 58-65, Exhibit 2023 pages 4-14, Exhibit 2024 pages 101, 102, 105-
`
`3
`
`
`
`
`112, and 114-118, and Exhibit 2025 pages 49-53 and 56-59 that cite or substantially
`
`Case IPR2022-00722
`U.S. Patent No. 7,041,786
`
`describe the NDA. Accordingly, there is good cause to grant this motion to seal.
`
`III. PROPOSED PROTECTIVE ORDER
`
`Pursuant to 37 C.F.R. § 42.54(a), the parties propose that the default
`
`protective order found in Appendix B of the Trial Practice Guide be entered.
`
`IV. CERTIFICATION OF NON-PUBLICATION
`
`
`
`The undersigned counsel certifies the information sought to be sealed by this
`
`Motion to Seal has not, to their knowledge, been published or otherwise made public.
`
`Patent Owner has made efforts to maintain the confidentiality of this information in
`
`a related district court proceeding. In that district court proceeding, the information
`
`that Patent Owner presently moves to seal has been produced and designated
`
`“Highly Confidential Information.”
`
`V. CONCLUSION
`
`For the reasons set forth above, Patent Owner respectfully requests the Board
`
`grant this motion to seal and enter the default Protective Order.
`
`
`
`Date: December 14, 2022
`
`Respectfully submitted,
`
`
`/Justin J. Hasford/
`By:
`Justin J. Hasford, Reg. No. 62,180
`Lead Counsel
`Bryan C. Diner, Reg. No. 32,409
`Back-up Counsel
`
`4
`
`
`
`
`
`
`
`Case IPR2022-00722
`U.S. Patent No. 7,041,786
`
`Joshua L. Goldberg, Reg. No. 59,369
`Back-up Counsel
`Kassandra M. Officer Reg. No. 74,083
`Back-up Counsel
`Lauren J. Robinson Reg. No. 74,100
`Back-up Counsel
`Caitlin E. O’Connell, Reg. No. 73,934
`Back-up Counsel
`Kyu Yun Kim, Reg. No. 72,783
`Back-up Counsel
`
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, L.L.P.
`901 New York Ave. NW
`Washington, DC 20001-4413
`(202) 408-4000
`
`Counsel for Patent Owner
`
`
`
`
`5
`
`
`
`Case IPR2022-00722
`U.S. Patent No. 7,041,786
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that a copy of the foregoing PATENT OWNER’S
`
`
`
`
`
`MOTION TO SEAL AND ENTER DEFAULT PROTECTIVE ORDER was
`
`served on December 14, 2022, via email directed to counsel of record for the
`
`Petitioner at the following:
`
`Jad A. Mills
`Wilson Sonsini Goodrich & Rosati PC
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`jmills@wsgr.com
`4863-5899-2145@mail.vault.netdocuments.com
`
`Richard Torczon
`Wilson Sonsini Goodrich & Rosati PC
`1700 K Street N.W., 5th Floor
`Washington, DC 20006
`rtorczon@wsgr.com
`
`Nicole W. Stafford
`Dennis D. Gregory
`Wilson Sonsini Goodrich & Rosati PC
`900 South Capital of Texas Highway, Las Cimas IV, Fifth Floor
`Austin, TX 78746-5546
`nstafford@wsgr.com
`dgregory@wsgr.com
`
`
`
`Dated: December 14, 2022
`
`
`
`
`
`
`
`
`
`
`
`/Lisa C. Hines/
`Lisa C. Hines
`Senior Litigation Legal Assistant
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER LLP
`
`
`
`
`
`6
`
`